ArticleJournal of clinical practice and research2025
Investigation of Interleukin-6 -572G/C Gene Polymorphism in Vitiligo Patients.
Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Vitiligo is a complex autoimmune condition characterized by the progressive destruction of melanocytes, resulting in patches of skin depigmentation. Interleukin-6 (IL-6), a multifunctional cytokine, has been linked to the development of various autoimmune diseases, including vitiligo. This study aims to investigate the association between the -572G/C polymorphism in the IL-6 gene and susceptibility to vitiligo. Materials and Methods: The study included 50 vitiligo patients and 50 healthy controls. Genetic analysis was conducted using DNA extracted from blood samples, followed by genotyping through polymerase chain reaction (PCR) and restriction fragment length polymorphism (RFLP) techniques. Results: The GG genotype was associated with a 2.53-fold increased risk of vitiligo (p=0.04, odds ratio (OR) [95% confidence interval (CI)] = 2.53 [1.03-6.23]), whereas the CG genotype significantly reduced this risk (p=0.04, OR [95% CI] = 0.39 [0.16-0.97]). A significant difference in allele frequencies was observed, with the G allele increasing the risk of vitiligo (p=0.03, OR [95% CI] = 2.39 [1.06-5.38]) and the C allele demonstrating a protective effect (p=0.03, OR [95% CI] = 0.42 [0.19-0.94]). Conclusion: The findings suggest that the GG genotype and G allele of the IL-6 -572G/C polymorphism are associated with an increased risk of vitiligo in the Turkish population, underscoring a potential role for IL-6 in the pathogenesis of the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.